Lumida
/INFU
⌘K
InfuSystem Holdings Inc

InfuSystem Holdings Inc

INFU
$8.92USD↓-3.46%-0.32 today

MARKET CAP

180.0M

P/E (TTM)

23.5x

FWD P/E

18.6x

DAY RANGE

$9 – $9

52W RANGE

$5
$11

AI Summary

Stalk
Sell NowMedium

INFU remains in a Stage 4 decline with successive lower highs and lower lows. Declining short- and intermediate-term moving averages are acting as resistance, and price has failed to reclaim the 9/21/50 EMA band. Short-term momentum shows no exhaustion signal, with price below the EMAs and RSI above oversold levels. The medium-term bias is bearish, and execution timing is favorable. Sell Now into rallies toward the EMA resistance zone, invalidated only by a sustained reclaim and acceptance above the key moving averages.

  • ↑6–8% annual revenue growth guided despite $7.1 M GE contract drag
  • ↑Adjusted EBITDA margin rose to 18.9%, targeting low-to-mid-20% range
  • ↓GE contract revision drives $7.1 M annual net revenue loss; Q1 rev down 3% to $33.7 M
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

InfuSystem Holdings, Inc. (NYSE: INFU) is a prominent player in the healthcare sector, specializing in infusion pumps and services related to oncology and wound care. The company focuses on enhancing patient management through innovative product offerings and operational improvements, positioning itself strategically within the medical device and healthcare services space. Its ongoing initiatives, such as the implementation of new technology systems and partnerships in wound care, suggest a strong commitment to navigating market challenges while expanding its service capabilities against a backdrop of increasing demand in the healthcare industry.

Bull says

  • ↑6–8% annual revenue growth guided despite $7.1 M GE contract drag
  • ↑Adjusted EBITDA margin rose to 18.9%, targeting low-to-mid-20% range
  • ↑Wound care sales surged 117% YoY via Smith & Nephew partnership
  • ↑CapEx cut to $1.3 M (from $2.6 M), liquidity remains strong at $57 M+
  • ↑$20 M buyback authorized and $0.8 M repurchased shows confidence
  • ↑Patient services revenue up 6.4% (+$1.3 M) on oncology and wound care demand

Bear says

  • ↓GE contract revision drives $7.1 M annual net revenue loss; Q1 rev down 3% to $33.7 M
  • ↓Analyst revisions trending lower, signaling deteriorating growth expectations
  • ↓ERP implementation issues reported, risking operational and billing delays
  • ↓Inflation and ERP costs may compress margins despite current uplift
  • ↓Competitive pressures and reimbursement changes could stall growth trajectory
  • ↓High short interest and elevated volatility suggest bearish investor sentiment

Investment themes with INFU

Health Care Providers↑ +0.29%

HCA · DGX · UHS
Seeking Alpha Top Rated Stocks↑ +0.32%

Highly rated stocks according to Seeking Alpha

MU · IRS · PBR

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-08-2026bullish

Transcript signals

Bull points

  • Despite the decrease in net revenue, gross profit for the first quarter of 2026 was $19.7 million, representing an increase of $515,000 or 3% over the prior year first quarter. The gross margin percentage at just over 58% increased by 3.2% from the prior year amount.
  • Adjusted EBITDA during the 2026 first quarter was $6.3 million, which, despite the lower net revenue, was about the same amount as the prior year first quarter. This represented 18.9% of net revenue for 2026, which was slightly above the prior year rate of 18.2%.
  • Our available liquidity continues to be strong and totaled just over $57 million as of March 31, 2026.

Bear points

  • Our net revenue totaled $33.7 million, representing a $1 million, or 3%, decrease from the prior year first quarter.
  • We do not think that anything is going to cause any disruptions in our cash flow or billings or anything like that.
  • We haven't yet seen a lift as of yet.
Read full transcript analysis ›